Hepion Pharmaceuticals, Inc.
HEPA- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583771
In the last 90 days, Hepion Pharmaceuticals, Inc. insiders filed 6 open-market purchases and 0 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $0 in total; no superinvestor holds it.
Other share classesCTRVP
Q3 2024 vs. Q2 2024
How the institutions holding Hepion Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 24 | 2 | 22 | 0 |
| Shares | 841.7K | 83.0K | 545.4K | −213.4K (−28.1%) |
| Value | $863.9K | $84.6K | $338.2K | −$441.1K (−56.6%) |
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Hepion Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Anson Funds Management LP | 231,849 | $128.2K | 0.02% |
| BlackRock, Inc. | 82,954 | $55.6K | 0.00% |
| Citadel Advisors LLC | 29,307 | $19.6K | 0.00% |
| Renaissance Technologies LLC | 16,564 | $11.1K | 0.00% |
Sold out (4)
Institutions that held Hepion Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Armistice Capital, LLC | 516,000 | $526.4K |
| Royal Bank of Canada | 14,520 | $15.0K |
| XTX Topco Ltd | 10,161 | $11.0K |
| Macquarie Group Ltd | 88 | $90 |
Not filed for Q3 2024 yet (2)
Institutions that held Hepion Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 82,954 | $84.6K |
| Benjamin F. Edwards & Company, Inc. | 1 | $0 |